Symbol | Exchange | Currency |
|---|
Nektar Therapeutics says it is on schedule for two key data readouts of bempegaldesleukin, its lead candidate under investigation for various types of cancer.
Nektar Therapeutics (NKTR): Q2 GAAP EPS of -$0.69 beats by $0.04.Revenue of $28.3M (-42.1% Y/Y) beats by $2.15M.Cash and investments in marketable securities at June 30, 2021...
Nektar Therapeutics (NASDAQ:NKTR) is scheduled to announce Q2 earnings results on Thursday, August 5th, after market close.The consensus EPS Estimate is -$0.73 (-62.2% Y/Y) and...
For Immediate ReleaseChicago, IL – February 25, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Sell | Sell | Strong Sell |
| Technical Indicators | Buy | Buy | Buy | Strong Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Neutral | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,725.00 | 2,727.00 | 2,696.90 | +22.5 | +0.83% | 893.45K | NASDAQ | |||
| 362.97 | 363.90 | 356.90 | +4.05 | +1.13% | 10.25M | NASDAQ | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 45.06 | 45.14 | 44.70 | -0.13 | -0.29% | 23.51M | NYSE | |||
| 169.40 | 169.88 | 165.13 | +2.61 | +1.56% | 354.45K | NYSE | |||
| 20.16 | 20.46 | 20.15 | +0.08 | +0.40% | 826.88K | NYSE | |||
| 23.22 | 23.33 | 23.14 | +0.11 | +0.48% | 2.62M | NYSE | |||
| 80.87 | 82.96 | 80.60 | -0.79 | -0.97% | 603.11K | NASDAQ | |||
| 19.56 | 19.82 | 19.22 | +0.50 | +2.62% | 6.96M | NYSE | |||
| 6.35 | 6.485 | 6.33 | -0.140 | -2.16% | 8.26M | NYSE | |||
| 61.83 | 63.33 | 61.74 | -1.49 | -2.35% | 715.96K | NYSE | |||
| 53.89 | 54.02 | 53.58 | +0.34 | +0.63% | 15.31M | NASDAQ | |||
| 1.10 | 1.12 | 1.06 | +0.0200 | +1.85% | 4.13M | NYSE | |||
| 21.26 | 21.66 | 21.21 | -0.39 | -1.80% | 11.55M | NYSE | |||
| 0.5627 | 0.00 | 0.00 | -0.0366 | -6.11% | 3.01M | NYSE |
Nektar Therapeutics operates as a biopharmaceutical company. The company researches and develops pipeline of investigational medicines in oncology, immunology, and virology, as well as a portfolio of approved partnered medicines. The company’s products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of non-small cell lung cancer and immuno-oncology; and phase 1B clinical trial to treat COVID-19.It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat locally advanced or metastatic solid tumor malignancies, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
